NAFLD (non-alcoholic fatty liver disease) and AF (atrial fibrillation) are two pathological conditions that are highly prevalent in developed countries and share multiple risk factors. The relationship between NAFLD and AF in Type 2 diabetes is currently unknown. We studied a hospital-based sample of 702 patients with Type 2 diabetes discharged from our Division of Endocrinology during 2007-2011. The diagnosis of AF was confirmed in affected participants on the basis of ECGs and medical history by experienced cardiologists. NAFLD was defined by ultrasonographic detection of hepatic steatosis in the absence of other liver diseases. Of the 702 hospitalized patients included in the study, 514 (73.2 %) of them had NAFLD and 85 (12.1 %) had persistent or permanent AF. NAFLD was associated with an increased risk of prevalent AF {OR (odds ratio), 3.04 [95 % CI (confidence interval), 1.54-6.02]; P < 0.001}. Adjustments for age, sex, systolic BP (blood pressure), HbA 1c , (glycated haemoglobin), estimated GFR (glomerular filtration rate), total cholesterol, electrocardiographic LVH (left ventricular hypertrophy), COPD (chronic obstructive pulmonary disease), and prior history of HF (heart failure), VHD (valvular heart disease) or hyperthyroidism did not attenuate the association between NAFLD and AF [adjusted OR, 5.88 (95 % CI, 2.72-12.7); P < 0.001]. In conclusion, our results show that ultrasound-diagnosed NAFLD is strongly associated with an increased prevalence of persistent or permanent AF in patients with Type 2 diabetes, independently of several clinical risk factors for AF. The potential impact of NAFLD on AF deserves particular attention, especially with respect to the implications for screening and surveillance strategies in the growing number of patients with NAFLD.
INTRODUCTION
NAFLD (non-alcoholic fatty liver disease) has become the most common cause of chronic liver disease in many developed and developing countries. NAFLD affects approximately 20-35 % of the general adult population in Western countries, and its prevalence increases to 70-90 % among persons with Type 2 diabetes or obesity, who are also at increased risk for the development of more severe forms of NAFLD, such as NASH (non-alcoholic steatohepatitis) and cirrhosis [1, 2] . NAFLD is closely associated with features of the metabolic syndrome and is now regarded as an additional component of the syndrome [1, 2] . Accumulating evidence indicates that NAFLD is linked to increased risk of CVD (cardiovascular disease) [3] . Recent studies also suggest that NAFLD is associated with early LV (left ventricular) diastolic dysfunction [4] [5] [6] , and that moderately elevated levels of serum GGT (γ -glutamyltransferase), as markers of NAFLD, are independently associated with an increased risk of incident HF (heart failure) [7, 8] .
In parallel, it is well recognized that AF (atrial fibrillation) is the most common sustained arrhythmia seen in clinical practice, and its prevalence and incidence are expected to increase substantially over the next few decades because of ageing population and improvements in cardiovascular treatments [9, 10] . This underscores the urgent need for primary prevention strategies against the development of AF. Along with older age, many pathological conditions such as obesity, hypertension, diabetes, IHD (ischaemic heart disease), VHD (valvular heart disease) and HF are important risk factors for new-onset AF [11, 12] , which is a disease associated with high rates of hospitalization and death [13, 14] .
Notably, the Framingham Heart Study investigators have recently reported an independent association between elevated serum transaminase levels, as proxy markers for NAFLD, and increased risk for incident AF in the community [15] . The potential impact of NAFLD on AF deserves particular attention, especially with respect to the implications for screening and surveillance strategies in the growing number of NAFLD patients.
To our knowledge, nobody has investigated the association between NAFLD and AF in people with Type 2 diabetes, a group of individuals in which these two diseases are highly prevalent. In an observational, age-and sex-matched cohort, longitudinal study of 34744 individuals with and without diabetes, Nichols et al. [16] have reported that AF was about 45 % more prevalent and about 40 % more likely to develop when diabetes was present.
The aim of the present study was to establish whether NAFLD as diagnosed by ultrasonography, which is a more precise measure of liver fat than serum transaminase concentrations [1] [2] [3] , is associated with a greater prevalence of AF in a large sample of patients with Type 2 diabetes.
MATERIALS AND METHODS

Patients
We identified all Caucasian patients with Type 2 diabetes, who were discharged from our Division of Endocrinology and Metabolism at the Verona University Hospital during 2007-2011. Where an individual had had multiple discharges in 2007-2011 the first discharge with complete data was considered for the statistical analysis. Most of these patients were admitted for chronic decompensated diabetes, diabetic foot ulcers or infections.
A total of 853 hospitalized patients with Type 2 diabetes were identified in our electronic database. The following patients were excluded: (i) patients with any clinical evidence of malignancies, ESRD (end-stage renal disease), acute hepatitis and cirrhosis of any aetiology (n = 37), (ii) those with excessive alcohol consumption (i.e. >20 g/day of alcohol for women and >30 g/day for men), viral hepatitis, drug-induced liver disease, iron overload or other secondary causes of chronic liver disease (n = 89) and (iii) those for whom a liver ultrasound examination was not available (n = 25). Patients with missing liver ultrasound data did not significantly differ from those who had liver ultrasound in terms of main clinical and biochemical features (results not shown).
As a result of this selection, 702 patients met the inclusion criteria of the study and were included in the final analysis.
The local ethics committee approved the study protocol. The informed consent requirement for the present study was exempted by the ethics committee because researchers only accessed retrospectively a de-identified database for analysis purposes.
Clinical and laboratory data
BMI was calculated by dividing weight in kilograms by the square of height in meters. BP (blood pressure) was measured in duplicate by a physician with a mercury sphygmomanometer (at the right upper arm using an appropriate cuff size) after participant had been seated quietly for at least 5 min. Patients were considered to have arterial hypertension if their BP was 140/90 mmHg or if they were taking any anti-hypertensive drugs. Information on daily alcohol consumption, smoking and current use of medications was obtained from all patients by questionnaire. In particular, alcohol consumption was assessed on the basis of the self-reported number of drinks consumed per day. The following amounts of alcoholic beverages were considered 1 drink: 330 ml of beer (containing ∼5 % of alcohol), 150 ml of wine (containing ∼12 % of alcohol) and 40 ml of strong alcohol (containing ∼50 % of alcohol).
Venous blood samples were drawn in the morning after an overnight fast. Serum liver enzymes, creatinine (measured using a Jaffé rate-blanked and compensated assay) and other biochemical blood measurements were determined using standard laboratory procedures (DAX 96; Bayer Diagnostics). Normal ranges for serum transaminase concentrations in our laboratory were 10-40 units/l for women and 10-50 units/l for men respectively; normal range for serum GGT concentration was 5-55 units/l for both sexes. LDL (low-density lipoprotein)-cholesterol was calculated by Friedewald equation, except when serum TAGs (triacylglycerols) exceeded 4.55 mmol/l (n = 14). Serum TSH (thyroid stimulating hormone) concentration was measured with a high-sensitivity immuno-chemiluminometric assay in all patients with AF and in those with history of thyroid disease or taking drugs interfering with biochemical thyroid status. HbA 1c (glycated haemoglobin) was measured by an automated HPLC analyser (Bio-Rad Diamat); the upper limit of normal for our laboratory was 5.6 %. GFR (glomerular filtration rate) was estimated from the four-variable Modification of Diet in Renal Disease study equation [16] . Albuminuria was measured by an immuno-nephelometric method on a morning spot urine sample and expressed as the albumin/creatinine ratio. CKD (chronic kidney disease) was defined as estimated GFR <60 ml/min/1.73 m 2 and/or abnormal albuminuria (defined as an albumin/creatinine ratio 30 mg/g) [17] .
IHD was defined as a documented history of myocardial infarction, angina, CABG (coronary artery bypass grafts), PTCA (percutaneous transluminal coronary angioplasty) or typical electrocardiographic abnormalities (according to the Minnesota code). Presence of peripheral artery disease was based on medical history and examination (e.g. intermittent claudication, rest pain, lower extremity revascularization procedures), and was confirmed by reviewing medical records of the hospital of patients, including radiology imaging results. The pre-existing history of VHD and HF were confirmed by reviewing medical records of the hospital, including diagnostic symptoms patterns, echocardiograms and results of other laboratory exams. The pre-existing history of COPD (chronic obstructive pulmonary disease) was confirmed by reviewing medical records of the hospital, including diagnostic symptoms patterns, and results of lung function tests. The pre-existing history of hyperthyroidism (mainly due to Graves' disease, toxic multinodular goitre, toxic adenoma or other less common aetiologies) was confirmed by reviewing medical records of the hospital, including hormone laboratory tests and thyroid imaging results. In most participants the presence of microvascular diabetic complications such as diabetic retinopathy (by fundoscopy after pupillary dilation) and lowerextremity sensory neuropathy (by biothesiometer) were also recorded.
ECGs and hepatic and carotid ultrasonography
A standard 12-lead ECG was performed in all patients during the hospital stay (and then repeated when necessary). A 24-h Holter monitor examination was not routinely performed. The diagnosis of paroxysmal, persistent or permanent AF was made on the basis of ECGs and medical history (from reviewing hospital and physician charts from all participants) [18] and confirmed in affected patients by experienced cardiologists, who were blinded to clinical characteristics of participants, including NAFLD status. Similarly, the diagnosis of electrocardiographic LVH (LV hypertrophy) was made according to Sokolow-Lyon's voltage criteria (SV1 + RV5 or RV6 3.5 mV) and/or Cornell's voltage criteria (SV3 + RaVL >2.0 mV in women and >2.8 mV in men respectively) [19] .
Hepatic ultrasonography was performed in all patients by experienced radiologists, who were blinded to subjects' characteristics. Hepatic steatosis was diagnosed on the basis of characteristic sonographic features, i.e. evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation and poor visualization of intra-hepatic vessel borders and diaphragm [20, 21] . It is known that ultrasonography has a good sensitivity and specificity for detecting moderate and severe hepatic steatosis (∼90-95 %), but its sensitivity is reduced when the hepatic fat infiltration upon liver biopsy is less than 33 % [21] . Semi-quantitative sonographic scoring for the degree of hepatic steatosis (mild, moderate or severe) was not available in the present study. Grading of hepatic fat content using ultrasonography has been used in previous studies but remains somewhat subjective [21] . As reported previously [20] , the intra-observer variability for the ultrasound diagnosis of hepatic steatosis was within 3 %.
The presence of atherosclerotic plaques (i.e. stenosis 30 %) at the level of either internal or common carotid arteries was diagnosed by echo-Doppler scanning, which was performed by specialist physicians, who were blind to subjects' characteristics.
Statistical analysis
Data are expressed as means + − S.D., medians (interquartile range) or percentages. Skewed variables (duration of diabetes, serum liver enzymes, TAGs and estimated GFR) were logarithmically transformed to improve normality prior to analysis. An unpaired Student's t test (for continuous variables) and a χ 2 test or the Fisher's exact test when appropriate (for categorical variables) were used to compare the clinical and biochemical characteristics of participants stratified by AF or NAFLD status. Logistic regression analysis was used to assess the independent association between NAFLD and prevalent AF after adjustment for potential confounders. For prediction of AF, men and women were combined and first-order interaction terms for sexby-NAFLD interactions on risk for AF were examined. Because the interactions were not statistically significant (P = 0.66), a sex-pooled multivariable regression analysis was used. Four logistic regression models were performed: an unadjusted model; a model adjusted for age and sex (model 1); a model further adjusted for systolic BP, HbA 1c , estimated GFR, total cholesterol, electrocardiographic LVH, COPD and pre-existing history of HF, VHD or hyperthyroidism (model 2); and, finally, a model further adjusted for serum GGT concentration and current use of any anti-hypertensive drugs, insulin, digoxin, anticoagulant and nitroderivate medications (model 3). These covariates were chosen as potential confounding factors on the basis of their significance in univariate analyses (Table 1) . A P value of <0.05 was considered statistically significant.
RESULTS
Of the 702 hospitalized patients included in the study, 514 (73.2 %; 228 women and 286 men) of them had NAFLD and 85 (12.1 %; 49 women and 36 men) had persistent or permanent AF. No patients had paroxysmal AF.
The characteristics of participants stratified by AF status are summarized in Table 1 . Compared with those without AF, patients with AF were older, more likely to be female, had lower values of systolic BP, HbA 1c , estimated GFR, total and LDL-cholesterol, and greater prevalences of hypertension, electrocardiographic LVH, CKD, COPD and carotid artery stenoses 30 %. They were also more likely to have a history of congestive HF, VHD and hyperthyroidism. The prevalence of peripheral artery disease and IHD tended also to be greater in patients with AF but did not reach a statistical significance. BMI, smoking, diabetic retinopathy, lower-extremity sensory neuropathy, use of ACEis (angiotensin-converting enzyme inhibitors), angiotensin receptor blockers, calcium channel blockers, α-blockers, lipid-lowering and oral hypoglycaemic drugs did not significantly differ between the two groups. Conversely, the proportion using β-blockers, diuretics, digoxin, nitroderivates and anticoagulants was higher in patients with AF whereas anti-platelet drugs and insulin therapy were less commonly used in these patients. Notably, as also shown in Table 1 , patients with AF had a greater prevalence of NAFLD on ultrasound than those without AF. These patients also had higher serum GGT levels, although the majority of our patients had serum GGT (∼80 %) and transaminase levels (∼90 %) within the reference ranges for our laboratory.
As expected, when patients were stratified by NAFLD status (Table 2) , all individual features of the metabolic syndrome (overweight/obesity, hypertension and atherogenic dyslipidaemia) occurred more frequently among patients with NAFLD. They also had higher values of HbA 1c and serum liver enzymes, although the vast majority of patients with NAFLD had normal serum AST (aspartate transaminase), ALT (alanine transaminase) and GGT levels. In addition, those with NAFLD were younger and had a shorter duration of diabetes than those without NAFLD. Notably, as also shown in Table 2 , there was a marked difference in the prevalence of AF among patients with and without NAFLD. Table 3 shows the association between NAFLD on ultrasound and prevalent AF and the effect of the adjustment for known risk factors on such association. In univariate analysis, NAFLD Figure 1 , when patients were stratified by the median value of serum GGT concentration (i.e. 32 units/l) and the NAFLD status on ultrasound, those with hepatic steatosis, irrespective of serum GGT level, showed the highest prevalence of AF. However, the presence of AF among those with low serum GGT ( 32 units/l) and without steatosis on ultrasound was negligible.
As shown in Table 3 , the association between NAFLD on ultrasound and prevalent AF remained statistically significant after adjusting for age and sex (model 1). Importantly, the strength of this association was not attenuated after further adjustment for 
DISCUSSION
NAFLD and AF are two pathological conditions that are highly prevalent in Western countries and share multiple CVD risk factors. To date, the published research on the association between AF and NAFLD (or liver function tests) is sparse. In a large retrospective cohort study, it has been reported that almost 28 % of outpatients with AF had abnormal ALT levels (i.e. defined as serum ALT >40 units/l) [22] . More interestingly, the investigators of the Framingham Heart Study have recently shown that elevated serum ALT or AST levels (>40 units/l for either marker) were associated with an increased risk of incident AF over a 10-year follow-up period, independently of common AF risk factors, in a community-based cohort of 3744 adults, who were free from clinical HF at baseline [15] .
The major finding of our study was that NAFLD on ultrasonography, which is a more precise measure of liver fat than serum transaminase concentrations, was strongly associated with an increased prevalence of persistent or permanent FA in a large hospital-based sample of Type 2 diabetic patients. The significance of this association was consistent in all subgroups evaluated. Notably, and more importantly, this association was independent of multiple clinical risk factors for AF. Serum GGT concentration was the only liver enzyme that was significantly associated with prevalent AF, but this significance was lost after controlling for potential confounders. Neither serum ALT nor serum AST levels were significantly associated with prevalent AF. Of note, most of our patients with Type 2 diabetes and NAFLD had 'normal' serum liver enzymes. This finding is consistent with earlier studies showing that the full histological spectrum of NAFLD may be present among patients with relatively normal liver enzymes [2, 23] . This suggests that serum liver enzyme levels are insensitive markers for the detection of NAFLD, and that the 'normal' reference values for serum liver enzymes currently used to exclude NAFLD need to be challenged and revised [2, 23] .
The older age and higher prevalence of hypertension, LVH, structural heart disease and other important co-morbidities we observed among those with AF are consistent with factors previously known to be associated with the presence and development of AF [9] [10] [11] [12] . Most of these pathological conditions cause LV diastolic dysfunction and left atrial enlargement, which may lead to fibrosis and electrical remodelling of the atrium, providing a pathophysiological substrate for subsequent development of AF [9, [24] [25] [26] .
Although there are few data on cardiac function among patients with NAFLD, preliminary evidence suggests that NAFLD is closely associated with early LV diastolic dysfunction [6] [7] [8] 27] . It is likely that LV diastolic dysfunction plays a role in AF pathogenesis either by increasing pressure that affects stretch receptors in pulmonary vein triggers and other areas of the atria or by inducing direct structural changes in atrial myocardium [24] [25] [26] . Interestingly, two large population-based cohort studies have also shown that moderately elevated serum GGT levels, as markers of NAFLD, are independently associated with an increased incidence of congestive HF [7, 8] .
The underlying mechanisms responsible for the observed association between NAFLD and AF remain speculative and require further study. Speculatively, the most obvious explanation for our findings is that NAFLD is associated with increased AF prevalence simply as a consequence of shared risk factors and comorbid conditions. However, it is important to note that in our study NAFLD was associated with prevalent AF, independently of age, sex, diabetes-related variables and important co-morbidities. Another possible explanation for our findings is that NAFLD is a marker of ectopic fat accumulation in other organs, including the myocardium and pericardium. It has been reported that myocardial steatosis was an independent predictor of LV diastolic dysfunction in patients with Type 2 diabetes, and that there was a significant, positive association between the intra-myocardial and intra-hepatic TAG content among these patients [28] . Recently, it has been also reported that increased pericardial fat was associated with both increased left atrial volume [29] and increased prevalence of AF [30] , independently of multiple established risk factors. Moreover, pericardial fat was larger in patients with AF than in matched controls, and was independently associated with left atrial remodelling in such patients [31] . Experimental evidence also suggests that adipocytes from epicardial, retrosternal or abdominal adipose tissues may modulate the electrophysiological properties and ion currents, causing higher arrhythmogenesis, in isolated rabbit left atrial myocytes [32] . Finally, since in our study NAFLD was associated with an increased prevalence of AF, independently of shared risk factors, it is also possible to speculate that NAFLD itself might actively contribute to the development and persistence of AF. This hypothesis is further corroborated by the recent data from the Framingham Heart Study demonstrating a positive and independent relationship between circulating liver transaminase concentrations and the risk of new-onset AF in the general adult population [15] . NAFLD may release a variety of pro-inflammatory and pro-coagulant mediators [e.g. CRP (C-reactive protein), IL-6 (interleukin-6), TNFα (tumour necrosis factor α) and other inflammatory cytokines] [33, 34] that play a role in the development and persistence of AF, possibly by inducing structural and/or electrical remodelling of the atria [35] [36] [37] . These pathways represent a novel pathogenic mechanism by which structural changes resulting from chronic inflammation can perpetuate AF. These findings require further testing and confirmation in larger clinical trials. Nevertheless, these pathways might provide a potential target for pharmacological interruption or reversal of atrial structural remodelling.
Our study has some important limitations. First, the design of our study is cross-sectional and cannot determine any causal or temporal relationship between NAFLD and AF. Secondly, we cannot exclude a possible selection bias of including a hospitalbased sample of Type 2 diabetic individuals so that the results cannot be generalizable directly to other diabetic populations. Thirdly, the diagnosis of NAFLD was based on patient history and ultrasound imaging, but was not confirmed by liver biopsy (which would be unacceptable to perform in our patients who had normal or only mildly elevated serum liver enzymes). Fourthly, the diagnosis of LVH was based on widely accepted ECG voltage criteria that have a very high specificity but a relatively low sensitivity when compared with echocardiographic findings [19] . Unfortunately, echocardiographic parameters were available only in few patients. However, we also adjusted our data for systolic BP and hypertension treatment, which are likely to capture almost all patients with LVH not detected by the classical ECG voltage criteria. Finally, we cannot exclude residual confounding.
Despite these limitations, our study has several strengths, including the large number of participants of both sexes, the diagnosis of NAFLD by ultrasonography, the complete nature of the dataset, and the ability to adjust for multiple clinical AF risk factors.
In conclusion, the present study is the first to document that ultrasound-diagnosed NAFLD is strongly associated with an increased prevalence of persistent or permanent AF in a large hospital-based sample of Type 2 diabetic patients. This association appears to be independent of several established risk factors for AF. Future research is required to elucidate the mechanisms responsible for this association and to determine whether NAFLD predicts the incidence and persistence of AF in people with Type 2 diabetes.
CLINICAL PERSPECTIVES
r NAFLD and AF are two pathological conditions that are highly prevalent in developed countries and share multiple risk factors. To date, the published research on the association between AF and NAFLD (or liver function tests) is sparse.
r In the present study, we examined the association between NAFLD and risk of prevalent AF in a large hospital-based sample of Type 2 diabetic patients. The study is the first to document that NAFLD on ultrasonography is associated with an increased prevalence of persistent or permanent AF, independently of several common risk factors for AF.
r These data should be viewed as hypothesis-generating. More research is urgently needed to corroborate a prognostic value of NAFLD for the incidence of AF, and to further elucidate the putative underlying mechanisms that link NAFLD and AF. In the interim, from the perspective of clinical practice, it is important that specialists and practicing clinicians be aware of the significant association between NAFLD and AF, especially because of the high and growing prevalence of these two pathologies.
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